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Osteoporosis is a major public health problem worldwide. Its complications are those 
related to fragility fractures, which cause considerable morbidity, mortality, and resource 
utilization. The socioeconomic burden is relatively well understood in the United States, but less 
studied in developing regions of the world. This paper will compare the epidemiology and 
socioeconomic burden of osteoporosis between the United States and Latin America. It will also 
review the current prevention, screening, diagnosis, and treatment methods, with an emphasis on 
raising awareness, improving management, and prioritizing osteoporosis as a public health 
problem. Information was gathered through a PubMed literature review and an interview with a 
provider from San Jose, Costa Rica. It is estimated that nearly 200 million elderly people suffer 
from osteoporosis worldwide. Geographical variances do exist; in general countries farther from 
the equator are at a greater risk. The National Osteoporosis Foundation (NOF) conducted a 
regionalized study that demonstrated the geographical variances, with the purpose to raise 
awareness, improve education, and incorporate more osteoporosis training in developing 
countries. The Latin American Vertebral Osteoporosis Study (LAVOS) determined that only 1 
out of 4 women over the age of 50 in Argentina had normal bone mineral density, demonstrating 
that osteoporosis is actually more common than previously thought in Latin America. Despite 
recent efforts to highlight its burden, osteoporosis is not considered a health priority in Latin 
America. There is a need to improve prevention strategies, clinical assessment, and raise 




 Osteoporosis is a major health concern that affects nearly half of the elderly population 
worldwide. The skeletal disease is oftentimes referred to as a “silent killer” because there are 
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often no presenting symptoms until a fracture occurs. Osteoporosis was previously thought to be 
a normal part of aging, but advances in medical research and technology have shifted this 
understanding. It is now considered preventable and treatable with more adequate screening 
measures and management guidelines available.1 Another challenge is that many of the fractures 
that occur as a result of osteoporosis happen without any trauma or significant mechanism of 
injury. Unfortunately, 1 in 3 women and 1 in 5 men over the age of 50 will experience an 
osteoporotic fracture in their lifetime.2 Osteoporotic fractures negatively impact quality of life 
and even lead to an increased rate of mortality in the elderly population.3  Furthermore, the 
prevalence of osteoporosis and its consequential fractures are only projected to rise with the 
world’s rapidly increasing elderly population.  
 Osteoporosis is a disease characterized by a decrease in bone mass, which predisposes 
individuals to an increased risk of fracture.4 It is estimated that nearly 200 million people are 
suffering from osteoporosis worldwide.5 In the United States, 1.5 million people suffer from 
osteoporotic fractures every year.3 Osteoporosis is four times more common in women than in 
men, with postmenopausal women at the highest risk. According to the United States 
Preventative Services Task Force (USPSTF), screening is recommended to begin at the age of 65 
for women, but no formal guidelines are available for assessing men.1 Men typically have greater 
bone mass, slower bone loss, and tend to have fractures 5-10 years later than women.6 The most 
commonly fractured sites are the vertebrae, hip, and wrist. The World Health Organization 
(WHO) recognizes that the majority of osteoporotic fractures occur as a result of low energy 
mechanical forces that would not ordinarily result in a fracture, referred to as a fragility fracture.  
The gold standard predictor of decreased bone mineral density (BMD) and resulting 
fracture risk is determined by using dual-energy x-ray absorptiometry (DXA) of the hip and 
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spine. The primary risk factor for developing osteoporosis is increasing age. Other factors 
include prolonged glucocorticoid therapy, excess alcohol intake, cigarette smoking, low levels of 
androgens, low physical activity, small body size, low vitamin D and calcium intake, and family 
history. Despite numerous identifiable factors, screening for and diagnosing osteoporosis is 
oftentimes overlooked, or simply forgotten. As a result, many cases of osteoporosis go unnoticed 
until a significant fragility fracture occurs. Unfortunately, research has shown that these fractures 
directly impact quality of life by increasing the likelihood of dependent living situations, 
permanent disability and in some cases even premature death.4      
  Osteoporotic-related fractures are a major global epidemic. The fragility fractures often 
require significant medical management, need for surgery, prolonged hospitalizations, long-term 
nursing home placement, and chronic pain management.7 A recent study analyzed over 200,000 
patients who had experienced an osteoporotic hip fracture and required surgery, 50% were 
permanently disabled, and 20% eventually led to premature death.8 Another prospective cohort 
study, over the course of eight years, followed a group of osteoporotic women who suffered 
vertebral fractures. The data revealed that these women had a 1.5-fold increased risk of dying of 
“other causes” while hospitalized, specifically, pulmonary disease and cancer.9  It should be 
noted that no single factor can predict an excess risk for cancer, chronic disease, or death. 
However, many well-conducted studies have depicted the staggering clinical consequences, cost, 
and worldwide societal impact associated with osteoporosis-related fractures in the elderly 
population.  
In addition to morbidity and mortality, osteoporosis poses an important public health 
concern due to the substantial medical costs associated with fragility fractures. The economic 
burden has been well-studied in the United States. The high medical costs are related to the 
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numerous consequences of an osteoporotic fracture: hospitalizations, surgery, outpatient care, 
long-term care, chronic pain management, disability, and even premature death.10 A study in the 
United States determined the estimated cost associated with osteoporotic fractures was US$17 
billion in 2005, likely higher now.3  A worldwide analysis also predicts that due to the increasing 
elderly population and longer life expectancies, the annual costs related to osteoporosis will 
exceed $132 billion by 2050.3  The Mayo Clinic compared hospital costs related to osteoporosis 
(US$ 5.1 billion), myocardial infarction (US$ 4.2 billion), stroke (US$ 3 billion), and breast 
cancer (US$0.5 billion).11 Although hospital costs associated with osteoporotic fracture 
complications were the greatest, osteoporosis is rarely considered a priority in many health 
systems and continues to be underdiagnosed and undertreated amidst the staggering economic 
losses.  
Osteoporosis is a common disorder that affects individuals and health systems 
worldwide. Its impact and economic burden are well-studied in the United States; however, less 
data are available in developing countries. Recently, new studies have begun to show similar 
socioeconomic burdens in other areas of the world. A study conducted in 2018 estimated the 
economic burden in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. 
The total combined cost associated with osteoporosis for the four countries was US$ 1.17 
billion.12 This cost is substantial, especially considering many of these countries have a smaller 
overall budget for medical care and resources. Many Latin American countries lack the facilities, 
screening tools, rehabilitation centers, evidence-based guidelines, and educated providers to 
properly treat osteoporosis. 13-15 A sobering study from a public university hospital in Venezuela 
focused on mortality rates following hip fractures; it found for those who did not receive surgery 
that the mortality rate was as high as 92% in the first year after the fragility fracture.15  
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Despite the recent efforts to highlight its growing economic burden, osteoporosis is not 
considered a health priority in many Latin American countries. There is a need to improve 
prevention strategies, clinical assessment, and raise awareness in these regions in order to lessen 
the considerable human and economic impact of the disease. This paper will compare the 
epidemiology and socioeconomic burden of osteoporosis between the United States and Latin 
America. It will also review the current prevention, screening, diagnosis and treatment methods 
of osteoporosis, with an emphasis on raising awareness, improving management, and prioritizing 




Osteoporosis affects people all over the world. Numerous factors contribute to overall 
bone health and osteoporotic fractures, but genetics and environment do play a role in the 
etiology.5 According to an analysis by The Endocrine Society in 2012, all populations are 
affected by osteoporosis, but not equally. There is an overall lack of multiregional studies, but 
recent research has demonstrated a geographic variance of the disease. Recently the International 
Osteoporosis Foundation (IOF) conducted regionalized research with the purpose to improve 
awareness, education, and training worldwide. Five epidemiological audits have been completed 
in the major regions of the world: Europe, Middle East, Africa, Asia-Pacific, and Latin America. 
The Latin American Regional Audit (LARA) was the first major analysis of the region and was 
completed in 2012 by a group of expert clinicians and national osteoporosis societies.14 
Importantly, the various audits revealed that indeed all areas of the world suffer from 
complications related to osteoporosis; however, the highest hip fracture rates were seen in 
Northern European countries. Asian countries demonstrated an intermediate risk, whereas Latin 
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America and Africa had the lowest overall risk.5,14 It is important to consider these 
epidemiologic variances, along with a thorough history, when determining an individual’s risk 
for developing osteoporosis.  
A limited number of recent reviews have revealed the differing rates of hip fractures and 
osteoporosis across ethnicities. The largest multiethnic study, the National Osteoporosis Risk 
Assessment (NORA), showed significant BMD variances across ethnicities.16 Black women had 
the highest BMD and white women had the lowest. Interestingly, Hispanic and Native American 
women’s measurements were not statistically different than white women.16 Additionally, an 
analysis of Europe found differences, as much as 7-fold, between northern and southern 
European countries.5 This study along with others have concluded that countries farther from the 
equator have a higher incidence of fracture. It is important to understand that a complex 
combination of factors ultimately affect bone mineral density, including genetics, gender, 
skeletal size, bodily calcium excretion, vitamin D intake in populations closer to the equator, and 
differences in diet pertaining to calcium intake.16,17  
It is evident there is a major gap in osteoporotic research across different geographic 
regions. In Latin America the lack of data is likely attributed to many factors, including, lack of 
national databases, surveillance methodology, reporting issues, and geographical and cultural 
barriers.18 It is worthwhile to track differences in fracture incidence in order to acknowledge 
osteoporosis as a major worldwide public health concern.5,15,18,19 Nearly all of the recent studies 
agree that due to the increasing lifespan and aging population, the rates of osteoporosis and 
devastating fractures are only going to become more apparent, especially in developing regions 
of the world.5 These countries lack the resources, diagnostic centers, and drug therapy to 
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properly manage fractures.20 These limitations combined with the lack of available data make it a 
challenge to address the burden of osteoporosis in certain ethnic groups and countries.  
With life expectancies increasing in nearly all regions of the world, the effects of 
osteoporosis are anticipated to become more widespread and detrimental.5 The relationship 
between ethnicity, BMD, and fracture risk is complex. Neither ethnicity nor geographic location 
alone can fully explain an individual’s risk for osteoporosis or subsequent fractures. A multitude 
of other factors contribute to bone health and fracture risk, including, lifestyle, skeletal strength, 
comorbidities, economic status and other social factors.16 Osteoporosis is an established problem 
in countries like the United States and Europe, with numerous health campaigns and accessible 
methods of diagnosis. In the last decade, data from developing countries are beginning to raise 
awareness and shed light on the serious complications of the condition. Although, more efforts 
are needed to prioritize osteoporosis in order to diminish the socioeconomic burden on 
individuals and health systems worldwide, especially in countries where medical resources are 
limited.4,15 In developing countries the magnitude of the problem is increased, and an 
individual’s experience presents with a disproportionate morbidity and mortality related to 
osteoporotic fractures.18 Thus, there is an urgent need to continue to gather epidemiological data 
on the burden of the disease to improve awareness and education to decrease fragility fracture 
incidence in all areas of the world. 
 
Latin America 
Despite the studied clinical and societal effects of osteoporosis, it remains 
underdiagnosed, undertreated and underrecognized. In 2012 the LARA the first of its kind to 
address the burden of osteoporosis in the 14-country region. One of the main findings was that 
Latin America’s elderly population is expected to increase by 280% in the next three decades, 
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which will undoubtedly lead to a problematic surge of osteoporosis and fragility fractures.14 
Another major concern is that many people in Latin America lack access to adequate screening 
methods and follow-up care, especially those living in the rural communities. Of the utmost 
concern is an overall lack of awareness, both on behalf of the medical providers and the patients. 
According to the Latin American Vertebral Osteoporosis Study (LAVOS), only 1 out of 4 
women over the age of 50 in Argentina had normal bone mineral density. Similarly, according to 
the WHO one of every 12 Mexican women over 50 years will sustain a hip fracutre.14  The 
findings demonstrate that osteoporosis and fragility fractures are actually quite common in Latin 
American, despite what may be discerned from its geographical proximity to the equator.13,14 
According to the LARA, statistics from the 14 countries were only slightly lower than similar 
studies of Caucasian women in Europe.14,21   
Costa Rica was included as one of the 14 Latin American countries. Significantly, Costa 
Rica is expected to have the greatest increase in the elderly population over the next three 
decades, with a percentage increase of 389%, higher than any other Latin American country.14 
The country currently operates on a statewide public health system, referred to as Social 
Security, which accounts for 92% of the population. Private healthcare options are also available 
to the public, but at a significant cost.14  In 1999 Costa Rica developed its own osteoporosis 
foundation, The Asoiacion Costarricense de Climaterio Menopausia y Osteoporosis 
(ACCMYO). With the help of ACCMYO, providers and the general population started to 
recognize osteoporosis. ACCMYO reported an alarming prevalence rate of 40% osteopenia and 
22% osteoporosis among postmenopausal Costa Rican women. Another significant study by 
ACCMYO found that of the 5,580 DXA scans completed, 63% were either diagnostic for 
osteopenia or osteoporosis; although, many of these patients did not receive a diagnosis nor did 
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they follow-up for preventative care.14 Overall, osteoporosis is a not recognized as a major health 
problem in Costa Rica, as there are no government funded health professional training programs 
or standard guidelines available. Furthermore, osteoporosis training is only incorporated into the 
medical school curriculum of endocrinologists and rheumatologists, so general doctors are not 
trained and are, thus poorly equipped to implement prevention strategies, diagnose, or provide 
care for those with osteoporosis.14 Actions are needed to improve osteoporosis training programs 
for all providers in order to recognize and treat patients at high risk for developing osteoporosis 




 The main goals of managing osteoporosis are (a) to promote prevention through non-
pharmacological and healthy lifestyle changes, (b) to identify high risk individuals with adequate 
screening methods and a thorough clinical history, and (c) to diagnose and begin 
pharmacological treatment to prevent future fractures.22 Multiple different organizations have 
provided evidence-based guidelines; here we will focus on those of the USPTF. The key to 
reducing the morbidity and mortality associated with fragility fractures according to USPTF is to 
place a greater emphasis on prevention and evaluation of known risk factors, as well as conduct 
formal imaging methods to screen patients.23  In 2011 the USPTF recommended screening all 
women over the age of 65. According to the USPTF there is insufficient evidence available to 
suggest recommendations for men. Therefore, the clinician should use his or her judgment and 
periodically perform individualized assessments in older men.1,6  When pertaining to the timing 
intervals between scans, the USPTF recommends a minimum of 2 years between screening 
measurements.24 As always the clinician should use his or her own judgement in determining if 
screening should occur sooner or more frequently based on a patient’s risk factors.22,23,25   
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Screening, diagnosis, and treatment of osteoporosis use BMD to assess bone strength, as 
determined by the most widely used method, or DXA. 22,26  DXA measures bone mineral density 
at the hip and spine. DXA scores compare the subject to a population at peak bone mass, which 
is referred to as the T-score. The World Health Organization (WHO) defines the diagnosis of 
osteoporosis as a low BMD with a T-score of -2.5 or less. A T-score between -1 and -2.5 is 
referred to as osteopenia.1 The diagnosis of osteoporosis can also be made by a single occurrence 
of a fragility fracture, whether or not a DXA scan has been obtained.25 Other techniques that are 
available, include peripheral DXA, computed tomography based absorptiometry, and 
quantitative ultrasound densitometry; although these are not preferred due to high radiation 
exposure and higher cost.27 Early detection and treatment of high-risk individuals, particularly 
post-menopausal women, is paramount in reducing hip fractures. 
 
Methods of screening in Latin America (Costa Rica) 
 
 The use of DXA and clinical assessment of risk factors are considered the most accurate 
predictors or “gold standard” for osteoporosis screening.1  However, in many developing regions 
of the world DXA is unavailable due to high cost, making diagnosing osteoporosis difficult.28 In 
regions where DXA is unavailable, a recently implemented alternative way to evaluate fracture 
risk is called the Fracture Risk Assessment Tool (FRAX). The tool uses a series of risk factors 
including, age, sex, height, weight, fracture history, rheumatoid arthritis, current tobacco 
smoking, steroid use, and alcohol intake to predict a patient’s 10-year fracture risk.29,30  The tool 
includes a section to manually insert a BMD measurement; however, this section can be omitted 
if DXA measurements are not available.18 A retrospective study was performed analyzing 239 
patients who underwent BMD measurement and FRAX. The study found that 86.61% of the 
patients had identical fracture risk predictions with or without the BMD incorporated into the 
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FRAX calculation. FRAX is an effective tool to predict osteoporotic fracture risk and would be 
an inexpensive, accessible, and alternative method when DXA is unavailble.30,31  
As discussed earlier in this paper there are geographic and ethnic differences that affect 
fracture risk, so FRAX can be specifically programmed to a particular country. It is predicted 
that nearly 127 countries are now using FRAX. In 2012 at the time of the LARA only four 
countries in Latin America were utilizing FRAX, but that has now doubled. In 2019 it is now 
being utilized in Argentina, Columbia, Ecuador, Mexico, Chile, Brazil, and Venezuela.14,18 The 
use of FRAX has grown and is incorporated into many country-specific guidelines for 
osteoporosis screening. It is now widely accessible, being available in 27 languages, 
incorporated into handheld calculators that do not require internet access, an application for 
smartphones, and even available in paper forms for patients to fill out themselves.31,32 The early 
detection of high-risk individuals is the foundation of osteoporosis management. The 
development of the FRAX tool plays a major role in lessening the impact of osteoporosis 
complications by identifying high-risk individuals, where DXA or other screening techniques 
may not be available.25  
 
Primary Prevention and Treatment  
In the past, osteoporosis was considered a normal part of aging; however, the bone 
disease is now considered to be preventable and treatable. Some of the most important aspects of 
primary prevention include adequate calcium and vitamin D intake, eating a healthy diet, 
increasing weight bearing exercise, refraining from smoking, and avoiding fall hazards.27 A 
meta-analysis examined the use of combined calcium and vitamin D supplementation for 
osteoporosis prevention in 11 different trials with over 30,000 participants. The analysis 
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concluded that the combination vs. placebo resulted in a statistically significant 30% decrease in 
hip fractures.33 Additionally, weight-bearing exercise not only improves balance and strength to 
prevent falls, but it has also been shown to actually increase bone mass.34 A recent Cochrane 
review concluded that resistance training and high force exercise did indeed prevent bone loss 
and fractures in postmenopausal women.23,34 Eating a healthy diet, as well as avoiding smoking 
and excess alcohol are also important components for promoting optimal bone health in order to 
prevent fragility fractures.27 Providers and the general public must first have an understanding of 
the true burden of osteoporosis to fully embrace the importance of preventative lifestyle 
measures.  
The treatment of osteoporosis combines preventative strategies and available 
pharmacologic agents. According to the NOF, postmenopausal women and men should be 
treated if they have a history of a fragility fracture or if their T-score is less than -2.5. Of note, 
the National Osteoporosis Foundation (NOF) recommends adequate calcium and vitamin D 
intake prior to incorporating other medical therapies, encouraging 1200mg/day for individuals 51 
and older and 800-1000 IU/day of Vitamin D for individuals 51 and older.1 Currently, 
bisphosphonates, which prevent or decrease bone loss, such as alendronate are considered first-
line therapy.32 Several studies have demonstrated that treatment significantly reduces fracture 
risk.1,23 According to a large meta-analysis, treatment with alendronate for three years increased 
BMD in postmenopausal women and those with established osteoporosis.35 A study comparing 
alendronate to a placebo demonstrated a significant 70% decrease in vertebral fractures.1,35,36 
Other pharmacologic agents exist such as selective estrogen-receptor modulators (SERMs), 
hormone therapy, parathyroid hormone, calcitonin, and denosumab. Bisphosphonates are 
considered first-line therapy primarily because of available long-term safety and efficacy data, 
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tolerability and cost effectiveness.1 The costs of bisphosphonates, taken once daily for up to 5 
years, vary in different regions of the world, but according to Farmacia CV in San Jose, Costa 
Rica the cost for 5 pills is only about US$ 7. According to the LARA when medically indicated 
pharmacological treatment can potentially be covered by Social Security. All told, medication 
therapy is considerably less than the direct hospital cost of a hip fracture, which is estimated to 
be US$ 8000. Furthermore, it should also be noted that this amount only accounts for the initial 
surgical treatment and does not include additional post-operative and social costs related to the 
fragility fractures, which would likely be significantly higher due to long-term care often needed 
following hip surgery. However, to date no studies have determined the all-encompassing 
economic impact of osteoporosis in Costa Rica.14   
 
Methods 
Literature searches were completed using PubMed database for prevention and 
management of osteoporosis in the United States, Latin America and Costa Rica. Search terms 
included: prevalence of osteoporosis in Latin America, burden of osteoporosis in Latin America, 
screening, prevention and treatment of osteoporosis, epidemiology of osteoporosis, incidence of 
osteoporotic hip fracture worldwide, and osteoporosis treatment. Interviews were conducted 





There is a sharp contrast between Latin America and the United States pertaining to the 
awareness, education, and prioritization of osteoporosis. The societal and economic impact of 
osteoporosis has been well documented in the United States, but in Latin America osteoporosis is 
considered a health priority in only three of the 14 countries analyzed.14 The combination of the 
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silent nature of the disease, lack of screening and diagnostic tools, and a limited health budget 
make it extraordinarily difficult to diagnose osteoporosis. Although some recent studies have 
now demonstrated that osteoporosis does have a greater impact than previously thought on 
elderly populations in regions closer to the equator.14,18 Unfortunately, its burden is only going to 
become more detrimental as the elderly population in Latin America is expected to triple by 
2050.12 A few distinct challenges exist in developing countries when implementing effective 
strategies to either prevent or treat diseases, including, fragmented health systems, cost and 
access to care, medical education, and overall awareness of the importance of a condition. One 
must consider methods that are cost effective, accessible, yet successful for prevention 
interventions and management.18  In Latin America, there is a demand for physicians, patients, 
health authorities, and the government to move osteoporosis up in the ladder of importance in 
order to reduce its disease burden.10,13,14,20 Especially given the morbidity, mortality and large 
economic impact of the disease, and the relatively cheap cost of preventative measures and 
pharmacologic agents, improvements are urgently needed in Latin America. By focusing on 
increasing the community’s understanding of osteoporosis, effective screening, treatment, and 
education strategies can be implemented to limit fracture complications.  
DXA was the first imaging tool developed for osteoporosis screening in the mid-
1980’s.27  In the United States and other industrialized regions DXA is considered relatively 
accessible; however, in developing regions it is extremely limited.18  According to interviews 
conducted with Dr. Luis Jimenez in Costa Rica, there are only three DXA Machines available to 
members of the Social Security system. Dr. Luis Jimenez also admitted that only certain 
providers can refer for the scans and that only very high-risk individuals are referred. Of these 
high-risk individuals many of them do not complete the scans because average wait times for a 
 16 
DXA scans can be up to two years.14 Another issue related to DXA utilization in Costa Rica is 
that the technicians who operate the equipment are seldomly certified by the International 
Society of Clinical Densitometry (ISCD), so this directly calls into question the quality and 
interpretation of the scans. Despite the incorporation of FRAX by many other countries, it is not 
used routinely in Costa Rica.14 Although in other Latin American countries, for example in 
Mexico, FRAX has been adapted to a paper test to make it more widely available. This approach 
using FRAX would help detect individuals who would otherwise potentially suffered an 
unnecessary fracture.   
There is an urgent need for (a) more widespread DXA equipment and (b) utilization of 
FRAX to improve diagnosis of osteoporosis in Latin America. Attention should be focused on 
implementing FRAX due to its accessibility, adaptability, and cheap cost. Some efforts have 
been made in training providers using webinars and courses.18  In 2012, it was estimated that 
over 10,000 primary care clinics in Latin America had started using FRAX, but not routeinely.18 
Some studies have determined that FRAX can be an effective alternative when DXA is limited, 
but more research is needed to demonstrate its effectiveness.29,30 The ongoing efforts to train 
providers on FRAX and the importance of obtaining a history that includes an analysis of risk 
factors are essential to detect high-risk individuals and prevent fragility fractures.  
Numerous studies have determined the effectiveness of pharmacologic treatments in 
reducing fractures.35,36 According to the LARA, pharmacologic agents are indeed available in all 
Latin America countries, but many patients do not properly receive prescriptions. The lack of 
treatment is largely due in part to countries not having standardized guidelines for osteoporosis 
management and the silent nature of the disease remaining undetected until a fragility fracture 
occurs. Furthermore, the NOF requires DXA measurements to make a formal diagnosis and 
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begin treatment.1  The problem with treating osteoporosis is further convoluted by the overall 
lack of awareness, both on behalf of the providers and the general public in regions like Latin 
America.18,20 According to Dr. Luis Jimenez, pharmacologic agents are available and covered in 
certain situations by Social Security in Costa Rica, but the majority of patients actually end up 
having to buy their own medications. Other pharmaceutical agents like ibandronate, zoledronate, 
denosumab, and teriparatide can be purchased by those who have private health care. Dr. Luis 
Jimenez also mentioned, “some doctors are reluctant to use osteoporosis medication due to rare 
side effects like osteonecrosis of the jaw and atypical fractures.” Despite the availability of 
effective and cheap treatment options, osteoporosis remains largely undiagnosed and therefore 
undertreated.  
Another component and challenge of treating osteoporosis with the first-line medication 
class, bisphosphonates, is that patients must have adequate vitamin D and calcium stores prior to 
using the medication.1 However, many individuals in Latin America do not consume enough 
calcium in their diets. A study conducted in Costa Rica examined vitamin D and calcium intake 
in adolescents. It found that 80% of those surveyed reported calcium intake less than the 
recommended level of 1,300 mg/d, with the lowest levels of reported dietary intake found among 
rural females.37 One of the largest dairy companies in Costa Rica, Dos Pinos, has been working 
with ACCYMO in an attempt to raise awareness, but more efforts are needed to educate the 
general public. The staggering lack of self-awareness pertaining to osteoporosis risk was 
examined in Brazil. Post-menopausal women were identified as being “high-risk” according to 
FRAX; of the high-risk women surveyed 80% identified as only having “little to no risk.”18 It is 
clear that there is a gap and misunderstanding of the importance and burden of osteoporosis, 
even among the groups at the highest risk. The use of the media and other public awareness 
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campaigns need to address proper nutrition, physical activity, smoking cessation, and the 
prevention of falls as directly related to osteoporosis.18 For example, in the United States three 
major organizations, Office of Women’s Health (OWH), NOF, and CDC worked together to 
generate a successful osteoporosis prevention campaign aimed at adolescent girls, called “Best 
Bones Forever,” among many others.38  Latin America must reevaluate the importance of using 
marketing strategies to improve prevention and management of osteoporosis, especially since 
preventative and evidence-based treatment options are widely available and affordable.39   
It is crucial to implement osteoporosis training into the medical education of primary 
providers, not just endocrinologists or orthopedists.18 Providers that deliver primary and 
secondary prevention are at the center of the issue and must be able to screen individuals and 
promote healthy lifestyles and prevention strategies in order to prevent fragility fractures.18,25 
With the help of more research, medical providers should be informed of the seriousness and 
burden of hip fractures on the health system, and retrained on how to detect and properly treat 
osteoporosis. Unfortunately, even with the best efforts targeted at medical providers, barriers will 
remain without funding and the acknowledgment from the government.18 The funding, 
campaigns, medical training, and guidelines rely on government activity.13,14,18  According to Dr. 
Luis Jimenez, some efforts to raise awareness in Costa Rica are currently underway: “We are 
planning on having some osteoporosis diagnosis workshops with two pharmaceutical companies. 
But the future is difficult, because the only way to improve diagnosis and treatment is to educate 
physicians and the public, but that requires funding and many of us cannot effort to pay.” Dr. 
Luis Jimenez explained that 10 years ago, around the time ACCMYO was founded, efforts were 
based primarily on pharmaceutical companies and the media with some support from providers. 
Although little progress has been made in the last decade according to Dr. Luis Jimenez: “It 
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seems that the medical community has forgotten a lot about osteoporosis.” This lack of 
awareness among the medical providers and general public makes it difficult for the government 
and other health societies to support or contribute financially to improve osteoporosis 
management.14 
Future strategies need to include more research and education demonstrating the 
socioeconomic burden in Latin America. The lack of awareness and gap in research leads to an 
ongoing neglection of the consequences of osteoporosis, which imparts an enormous toll on 
populations. Strategies to raise awareness are complex and require the cooperation of many 
groups: general public, providers, health authorities, and governmental policy makers.14,18 All 
told, until these groups reevaluate the importance of osteoporosis prevention, screening and 
treatment, unnecessary fractures will continue to negatively impact individuals, as well as the 




In conclusion, osteoporosis is a major public health problem that imposes a serious 
socioeconomic burden on health systems worldwide. Osteoporosis-related fractures lead to 
considerable morbidity, mortality, and resource utilization. Unfortunately, in developing 
countries like those in Latin America its impact is not as well-studied or understood. As a result, 
osteoporosis is continually undiagnosed and untreated. On account of the dramatically increasing 
aging population, the effects of the disease are likely going to become more widespread and 
problematic. It is predicted that the worldwide incidence of hip fracture will rise to affect nearly 
6.26 million people by the year 2050 with an annual cost of nearly US$ 13 billion.5  
Furthermore, Latin America has limited health resources, diagnostic tools (DXA and FRAX), 
treatment, rehabilitation centers, and funding.15 These issues combined with the lack of 
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awareness and proper provider education, will continue to take a toll on the population and 
health budget in Latin America.13  The socioeconomic burden and projected exponential increase 
of osteoporotic fractures demand attention for adequate, yet cost effective, improvements in 
awareness, prevention, screening, and treatment methods.  
 The recognition of osteoporosis as a major health priority in Latin America is required in 
order for the effects of osteoporosis to be understood. The collective collaboration and financial 
support of many different groups such as the national government, medical specialists, patients 
and the general public are needed in order to implement new strategies, and to reevaluate 
osteoporosis management. Improvements should focus on educating providers on the seriousness 
of osteoporosis in order to implement effective diagnostic technology, such as FRAX and DXA, 
which combined with known risk factors can effectively detect high-risk individuals. Latin 
America must first recognize osteoporosis as a major health priority in order to place a stronger 
emphasis on prevention and ultimately improve management, and lessen the human and 
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